258 related articles for article (PubMed ID: 17259170)
1. Reversible monoubiquitination regulates the Parkinson disease-associated ubiquitin hydrolase UCH-L1.
Meray RK; Lansbury PT
J Biol Chem; 2007 Apr; 282(14):10567-75. PubMed ID: 17259170
[TBL] [Abstract][Full Text] [Related]
2. Substrate recognition and catalysis by UCH-L1.
Luchansky SJ; Lansbury PT; Stein RL
Biochemistry; 2006 Dec; 45(49):14717-25. PubMed ID: 17144664
[TBL] [Abstract][Full Text] [Related]
3. Ubiquitin dimers control the hydrolase activity of UCH-L3.
Setsuie R; Sakurai M; Sakaguchi Y; Wada K
Neurochem Int; 2009; 54(5-6):314-21. PubMed ID: 19154770
[TBL] [Abstract][Full Text] [Related]
4. Ubiquitin C-Terminal Hydrolase L1 (UCH-L1) Promotes Hippocampus-Dependent Memory via Its Deubiquitinating Effect on TrkB.
Guo YY; Lu Y; Zheng Y; Chen XR; Dong JL; Yuan RR; Huang SH; Yu H; Wang Y; Chen ZY; Su B
J Neurosci; 2017 Jun; 37(25):5978-5995. PubMed ID: 28500221
[TBL] [Abstract][Full Text] [Related]
5. Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron.
Osaka H; Wang YL; Takada K; Takizawa S; Setsuie R; Li H; Sato Y; Nishikawa K; Sun YJ; Sakurai M; Harada T; Hara Y; Kimura I; Chiba S; Namikawa K; Kiyama H; Noda M; Aoki S; Wada K
Hum Mol Genet; 2003 Aug; 12(16):1945-58. PubMed ID: 12913066
[TBL] [Abstract][Full Text] [Related]
6. The ubiquitin C-terminal hydrolase L1 (UCH-L1) C terminus plays a key role in protein stability, but its farnesylation is not required for membrane association in primary neurons.
Bishop P; Rubin P; Thomson AR; Rocca D; Henley JM
J Biol Chem; 2014 Dec; 289(52):36140-9. PubMed ID: 25326379
[TBL] [Abstract][Full Text] [Related]
7. Ubiquitin C-terminal hydrolase-L1 increases cancer cell invasion by modulating hydrogen peroxide generated via NADPH oxidase 4.
Kim HJ; Magesh V; Lee JJ; Kim S; Knaus UG; Lee KJ
Oncotarget; 2015 Jun; 6(18):16287-303. PubMed ID: 25915537
[TBL] [Abstract][Full Text] [Related]
8. UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease.
Ardley HC; Scott GB; Rose SA; Tan NG; Robinson PA
J Neurochem; 2004 Jul; 90(2):379-91. PubMed ID: 15228595
[TBL] [Abstract][Full Text] [Related]
9. Parkin-mediated K63-polyubiquitination targets ubiquitin C-terminal hydrolase L1 for degradation by the autophagy-lysosome system.
McKeon JE; Sha D; Li L; Chin LS
Cell Mol Life Sci; 2015 May; 72(9):1811-24. PubMed ID: 25403879
[TBL] [Abstract][Full Text] [Related]
10. Membrane-associated farnesylated UCH-L1 promotes alpha-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease.
Liu Z; Meray RK; Grammatopoulos TN; Fredenburg RA; Cookson MR; Liu Y; Logan T; Lansbury PT
Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4635-40. PubMed ID: 19261853
[TBL] [Abstract][Full Text] [Related]
11. Aberrant interaction between Parkinson disease-associated mutant UCH-L1 and the lysosomal receptor for chaperone-mediated autophagy.
Kabuta T; Furuta A; Aoki S; Furuta K; Wada K
J Biol Chem; 2008 Aug; 283(35):23731-8. PubMed ID: 18550537
[TBL] [Abstract][Full Text] [Related]
12. Development of Ubiquitin Variants with Selectivity for Ubiquitin C-Terminal Hydrolase Deubiquitinases.
Hewitt CS; Krabill AD; Das C; Flaherty DP
Biochemistry; 2020 Sep; 59(37):3447-3462. PubMed ID: 32865982
[TBL] [Abstract][Full Text] [Related]
13. Endogenous neurotoxic dopamine derivative covalently binds to Parkinson's disease-associated ubiquitin C-terminal hydrolase L1 and alters its structure and function.
Contu VR; Kotake Y; Toyama T; Okuda K; Miyara M; Sakamoto S; Samizo S; Sanoh S; Kumagai Y; Ohta S
J Neurochem; 2014 Sep; 130(6):826-38. PubMed ID: 24832624
[TBL] [Abstract][Full Text] [Related]
14. Ubiquitin C-terminal hydrolase L1 (UCH-L1): structure, distribution and roles in brain function and dysfunction.
Bishop P; Rocca D; Henley JM
Biochem J; 2016 Aug; 473(16):2453-62. PubMed ID: 27515257
[TBL] [Abstract][Full Text] [Related]
15. Ubiquitin C-terminal hydrolase L1 (UCH-L1) acts as a novel potentiator of cyclin-dependent kinases to enhance cell proliferation independently of its hydrolase activity.
Kabuta T; Mitsui T; Takahashi M; Fujiwara Y; Kabuta C; Konya C; Tsuchiya Y; Hatanaka Y; Uchida K; Hohjoh H; Wada K
J Biol Chem; 2013 May; 288(18):12615-26. PubMed ID: 23543736
[TBL] [Abstract][Full Text] [Related]
16. S-Mercuration of ubiquitin carboxyl-terminal hydrolase L1 through Cys152 by methylmercury causes inhibition of its catalytic activity and reduction of monoubiquitin levels in SH-SY5Y cells.
Toyama T; Abiko Y; Katayama Y; Kaji T; Kumagai Y
J Toxicol Sci; 2015 Dec; 40(6):887-93. PubMed ID: 26558469
[TBL] [Abstract][Full Text] [Related]
17. β-Amyloid (Aβ) oligomers impair brain-derived neurotrophic factor retrograde trafficking by down-regulating ubiquitin C-terminal hydrolase, UCH-L1.
Poon WW; Carlos AJ; Aguilar BL; Berchtold NC; Kawano CK; Zograbyan V; Yaopruke T; Shelanski M; Cotman CW
J Biol Chem; 2013 Jun; 288(23):16937-16948. PubMed ID: 23599427
[TBL] [Abstract][Full Text] [Related]
18. The evolutionarily conserved deubiquitinase UBH1/UCH-L1 augments DAF7/TGF-β signaling, inhibits dauer larva formation, and enhances lung tumorigenesis.
Nagata A; Itoh F; Sasho A; Sugita K; Suzuki R; Hinata H; Shimoda Y; Suzuki E; Maemoto Y; Inagawa T; Fujikawa Y; Ikeda E; Fujii C; Inoue H
J Biol Chem; 2020 Jul; 295(27):9105-9120. PubMed ID: 32371398
[TBL] [Abstract][Full Text] [Related]
19. Glutathione-mediated reversibility of covalent modification of ubiquitin carboxyl-terminal hydrolase L1 by 1,2-naphthoquinone through Cys152, but not Lys4.
Toyama T; Shinkai Y; Yazawa A; Kakehashi H; Kaji T; Kumagai Y
Chem Biol Interact; 2014 May; 214():41-8. PubMed ID: 24582816
[TBL] [Abstract][Full Text] [Related]
20. The potential role of ubiquitin c-terminal hydrolases in oncogenesis.
Fang Y; Fu D; Shen XZ
Biochim Biophys Acta; 2010 Aug; 1806(1):1-6. PubMed ID: 20302916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
